Trial Profile
Vicriviroc in Combination Treatment With an Optimized ART [antiretroviral] Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Vicriviroc (Primary)
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Acronyms VICTOR-E2
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 16 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.